June 26, 2024

Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the efficacy and safety of lenvatinib plus pembrolizumab in these patients.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

French et al. (Wed,) studied this question.

synapsesocial.com/papers/68e6327cb6db6435875c4219 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-23-3417

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma2019 · 42 citations
2Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy2006 · 1,671 citations
3Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges2018 · 1,963 citations
4Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma2021 · 1,768 citations
5PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer2015 · 89 citations

Preguntar a la IA

Me gusta

Guardar